CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma
CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma
复制标题
DOI：
10.1093/annonc/mdg253
复制
发表时间：
2003-06-01
影响因子：
50.5
通讯作者：
Koch, M
中科院分区：
文献类型：
--
作者：
Potti, A;Moazzam, N;Koch, M
背景：本研究的目的是确定 CD117 (c-KIT) 过度表达的发生率和作为广泛期小细胞肺癌 (ESSCLC) 预测/预后标志物的作用。我们对经活检证实诊断为 ESSCLC 的受试者进行了一项回顾性研究。患者和方法：对 1991 年至 2001 年间诊断的 ESSCLC 患者进行了人口统计和临床数据的图表审查。使用对档案石蜡包埋标本进行的免疫组织化学（A4052 多克隆抗体）评估 CD117 过度表达。结果：223 名 ESSCLC 患者被纳入研究。经鉴定，其中 193 名（84 名女性，109 名男性）平均年龄为 68.5 岁（范围 42-90 岁）有足够的组织样本可用于 CD117 检测。最常见的症状是体重减轻，有 61 名患者 (31.6%) 出现。在 193 个样本中，54 个（27.9%）显示 CD117 过度表达。 CD117 阳性患者的中位生存期为 9 个月，而 CD117 阴性人群的生存期为 6 个月（P = 0.025，Cox 比例风险法）。结论：使用免疫组织化学检测到的 CD117 过表达在约三分之一的 ESCLC 患者中观察到，并且不具有统计学意义的预后价值。然而，CD117 可能是 ESSCLC 位点特异性免疫治疗的潜在靶点。我们的研究结果表明，评估选择性酪氨酸激酶抑制剂 STI-571（单独或与常规疗法联合）对 ESSCLC 患者的作用的临床试验具有重要意义。
Background: The aim of this study was to determine the incidence and role of CD117 (c-KIT) overexpression as a predictive/prognostic marker in extensive-stage small-cell lung carcinoma (ESSCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of ESSCLC.Patients and methods: A chart review for demographic and clinical data was performed on patients with ESSCLC diagnosed between 1991 and 2001. CD117 overexpression was evaluated using immunohistochemistry (A4052 polyclonal antibody) performed on archival paraffin-embedded specimens.Results: Two hundred and twenty-three patients with ESSCLC were identified, of whom 193 (84 females, 109 males) with a mean age of 68.5 years (range 42-90) had adequate tissue specimens available for CD117 testing. The most commonly presenting symptom was weight loss, seen in 61 patients (31.6%). Of the 193 specimens, 54 (27.9%) showed CD117 overexpression. The median length of survival for CD117-positive patients was 9 months as compared with the CD117-negative population, in whom the survival was 6 months (P = 0.025, Cox proportional hazard method).Conclusions: CD117 overexpression detected using immunohistochemistry is observed in about a third of patients with ESSCLC and does not have statistically significant prognostic value. However, CD117 may be a potential target for site-specific immunotherapy in ESSCLC. Our findings suggest a role for clinical trials assessing the role of selective tyrosine kinase inhibitor STI-571 (alone or in combination with conventional therapy) in patients with ESSCLC.